In Good Company with Nicolai Tangen

Rerun: Lars Fruergaard Jørgensen CEO of Novo Nordisk

Jul 24, 2024

Lars Fruergaard Jørgensen, CEO of Novo Nordisk, dives into the pressing issue of obesity as a complex health crisis. He shares insights on the company's innovative GLP-1 medication, addressing the major challenges of accessibility in Europe and the U.S. Jørgensen emphasizes the significance of purpose in the pharmaceutical industry and reflects on grounded leadership principles. The discussion also touches on navigating cultural differences in global teams and the value of non-linear career paths for fostering a sustainable work-life balance.

38:48

Creator website

Episode guests

Lars Fruergaard Jorgensen

AI Summary

AI Chapters

Episode notes

Podcast summary created with Snipd AI

Quick takeaways

Obesity is recognized as a disease influenced by genetics, necessitating effective medications for treatment.

Global obesity is a universal issue affected by socioeconomic factors, societal structures, and easy access to unhealthy food.

Deep dives

Obesity is a Recognized Disease with Genetic and Lifestyle Factors

Obesity has tripled since 1975, with over 1 billion obese individuals globally. While often attributed to lifestyle choices, it is now recognized as a disease influenced by genetics. Novo Nordisk's research has shown that different people face varied physiological challenges, making traditional weight management difficult, thereby highlighting the necessity for effective medications in combating obesity.

Intro

4min

The Societal Challenge of Obesity and the Importance of Prevention

2min

Innovations and Challenges in Obesity Treatment

17min

Navigating Cultural Differences in Global Corporate Environments

3min

Grounded Leadership in Pharmaceuticals

10min

Embracing Non-Linear Career Paths for a Sustainable Future

3min

Rerun:

“I'm very concerned that European citizens will have lack of access or much lower access to some of the new medicines” says CEO of Novo Nordisk. He also share some interesting perspectives about the importance of purpose and their new weight loss drug.

The production team on this episode were PLAN-B’s Niklas Figenschau Johansen and Nikolai Ovenberg. Background research was done by Sigurd Brekke with input from portfolio manager Gemma Game.